Imagine being told your lung cancer has stopped responding to treatment. Then imagine your doctor tries a different order of the same drugs, and the tumors start shrinking again.
That is exactly what happened to a 79-year-old man with advanced non-small cell lung cancer (NSCLC). His case, published in Frontiers in Medicine, offers a surprising clue for thousands of patients facing drug resistance.
Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer makes up about 85 percent of all cases. For many patients, the cancer carries specific genetic changes called mutations. Two of the most important are MET exon 14 skipping mutations and high levels of a protein called PD-L1.
Doctors have drugs that target each of these. But they did not know the best order to give them. This case suggests the order may matter more than anyone realized.
The old way vs. what changed
The standard approach has been to treat one problem at a time. If a patient has high PD-L1, give immunotherapy. If a MET mutation appears, give a MET inhibitor.
But here is the twist. The cancer can learn to dodge these drugs. It finds new ways to grow. Doctors call this acquired resistance. And once resistance sets in, they often assume that drug will never work again.
This case challenges that assumption.
Think of the cancer as a locked door. Immunotherapy is one key. MET inhibitors are another key. When the first key stops working, you might assume the lock has changed. But this case suggests that using the second key first can reset the lock. Then the first key works again.
The cancer cells in this patient had two important features. First, they had a broken MET gene. This gene acts like a stuck accelerator pedal. It tells the cells to keep growing and dividing. Second, the cells had very high PD-L1. This is like a "do not eat me" sign that tricks the immune system into leaving the cancer alone.
Immunotherapy drugs remove that sign. They let the immune system attack. MET inhibitors fix the stuck accelerator. They slow down the growth signal.
The trick is that these two systems talk to each other. When one pathway gets blocked, the other can change. The tumor environment shifts. This case suggests that blocking the MET pathway first can make the tumor vulnerable to immunotherapy again.
The patient was a 79-year-old man who had quit smoking 20 years earlier. His tumor had a PD-L1 score of 99 percent. That is extremely high. It also had a MET exon 14 skipping mutation.
Doctors started him on an immunotherapy drug called Tislelizumab. This is a PD-1 inhibitor. It worked well for 7 months. Then the cancer started growing again.
They switched him to a MET inhibitor called Savolitinib. This drug targets the broken MET gene. The tumors shrank noticeably.
But then a problem emerged. The Savolitinib caused liver damage. The patient had to stop taking it.
At this point, the doctors faced a tough choice. The immunotherapy had stopped working months earlier. Normally, you would not try it again. But they decided to give Tislelizumab another chance.
It worked.
The tumors came back under control. The drug that had failed before was now effective again.
This does not mean every patient should try this sequence on their own.
What this means for patients
This is a single case report. That means it is one person's story. It is not a large clinical trial. Doctors cannot change standard treatment based on one case alone.
But it does give them a new idea to consider. For patients with both a MET mutation and high PD-L1, the order of drugs may be critical. Using a MET inhibitor first might reset the tumor environment. Then immunotherapy could work again even after resistance.
If you or a loved one has advanced lung cancer, talk to your oncologist about your specific mutations. Ask whether your tumor has been tested for MET changes and PD-L1 levels. These tests guide treatment decisions.
The honest limits
This is one patient. His results may not apply to everyone. The liver damage from Savolitinib forced the drug switch. That is not a planned strategy. It was a reaction to a side effect.
Also, the patient had a very high PD-L1 score. Most patients do not have a 99 percent score. The results may differ for people with lower levels.
The researchers themselves call this a "distinctive therapeutic sequence." They are not claiming it is ready for widespread use.
What happens next
More research is needed. Doctors need to test this approach in larger groups of patients. Clinical trials could compare different drug sequences head to head.
The researchers also want to understand why the sequence works. They suspect the MET inhibitor changes the tumor environment in a way that makes immunotherapy effective again. But they need to prove this in the lab.
For now, this case adds one more piece to the puzzle. It shows that drug resistance does not always mean a drug is useless forever. Sometimes the right sequence can bring it back to life.
Science moves slowly for a reason. Each case builds on the last. And one patient's story can open a door for many others.
